SwePub
Tyck till om SwePub Sök här!
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Poikonen Saksela Paula)
 

Sökning: WFRF:(Poikonen Saksela Paula) > Lahdenperä Outi > Adjuvant Capecitabi...

  • Joensuu, HeikkiHelsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (författare)

Adjuvant Capecitabine for Early Breast Cancer : 15-Year Overall Survival Results From a Randomized Trial

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • American Society of Clinical Oncology (ASCO),2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-476622
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-476622URI
  • https://doi.org/10.1200/JCO.21.02054DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer.METHODS: The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates integration of capecitabine to an adjuvant chemotherapy regimen containing a taxane and an anthracycline for the treatment of early breast cancer. Between January 27, 2004, and May 29, 2007, 1,500 patients with axillary node-positive or high-risk node-negative early breast cancer were accrued. The patients were randomly allocated to either TX-CEX, consisting of three cycles of docetaxel (T) plus capecitabine (X) followed by three cycles of cyclophosphamide, epirubicin, and capecitabine (CEX, 753 patients), or to T-CEF, consisting of three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil (CEF, 747 patients). We performed a protocol-scheduled analysis of overall survival on the basis of approximately 15-year follow-up of the patients.RESULTS: The data collection was locked on December 31, 2020. By this date, the median follow-up time of the patients alive was 15.3 years (interquartile range, 14.5-16.1 years) in the TX-CEX group and 15.4 years (interquartile range, 14.8-16.0 years) in the T-CEF group. Patients assigned to TX-CEX survived longer than those assigned to T-CEF (hazard ratio 0.81; 95% CI, 0.66 to 0.99; P = .037). The 15-year survival rate was 77.6% in the TX-CEX group and 73.3% in the T-CEF group. In exploratory subgroup analyses, patients with estrogen receptor-negative cancer and those with triple-negative cancer treated with TX-CEX tended to live longer than those treated with T-CEF.CONCLUSION: Addition of capecitabine to a chemotherapy regimen that contained docetaxel, epirubicin, and cyclophosphamide prolonged the survival of patients with early breast cancer.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Kellokumpu-Lehtinen, Pirkko-LiisaTampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland. (författare)
  • Huovinen, RiikkaTurku Univ Hosp, Dept Oncol, Turku, Finland. (författare)
  • Jukkola, ArjaTampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland.;Oulu Univ Hosp, Dept Radiotherapy & Oncol, Oulu, Finland. (författare)
  • Tanner, MinnaTampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland. (författare)
  • Ahlgren, JohanGävle Cent Hosp, Gävle, Sweden.;Acad Hosp, Reg Canc Ctr Mid Sweden, Uppsala, Sweden. (författare)
  • Auvinen, PäiviKuopio Univ Hosp, Ctr Canc, Kuopio, Finland. (författare)
  • Lahdenperä, OutiTurku Univ Hosp, Dept Oncol, Turku, Finland. (författare)
  • Villman, KennethÖrebro Univ Hosp, Örebro, Sweden. (författare)
  • Nyandoto, PaulPaijat Hame Cent Hosp, Lahti, Finland. (författare)
  • Nilsson, GregerUppsala universitet,Experimentell och klinisk onkologi,Gävle Cent Hosp, Dept Oncol, Sweden.;Visby Hosp, Sweden.(Swepub:uu)grnil933 (författare)
  • Poikonen-Saksela, PaulaHelsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (författare)
  • Kataja, VesaCent Finland Cent Hosp, Jyvaskyla, Finland. (författare)
  • Bono, PetriHelsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland. (författare)
  • Junnila, JouniEstiMates, Turku, Finland. (författare)
  • Lindman, HenrikUppsala universitet,Experimentell och klinisk onkologi(Swepub:uu)henrlind (författare)
  • Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland.Tampere Univ Hosp, Dept Oncol, Tampere, Finland.;Tampere Univ, Tampere, Finland. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical Oncology: American Society of Clinical Oncology (ASCO)40:10, s. 1051-10580732-183X1527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy